Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOFH1M)

Drug Name
Volasertib Drug Info
Synonyms
Volasertib; 755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Cross-matching ID
PubChem CID
10461508
CAS Number
CAS 755038-65-4
TTD Drug ID
DMOFH1M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Polo-like kinase 1 (PLK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rigosertib DMOSTXF Myelodysplastic syndrome 2A37 Phase 3 [3]
PCM-075 DMYFRTB Acute myeloid leukaemia 2A60 Phase 2 [4]
BI 2536 DMJSADP Acute myeloid leukaemia 2A60 Phase 2 [5]
MK-1496 DME1ZAH Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
GSK461364 DM0P729 Non-hodgkin lymphoma 2B33.5 Phase 1 [5]
TAK-960 DMN4OGH Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
CYC140 DMC6PKJ Acute myeloid leukaemia 2A60 Phase 1 [8]
Dihydropyrido pyrazinone compound 3 DM3PEUN N. A. N. A. Patented [9]
Dihydropyrido pyrazinone compound 2 DMOTG2Y N. A. N. A. Patented [9]
HMN-214 DMH4ANG Pancreatic cancer 2C10 Discontinued in Phase 1 [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Polo-like kinase 1 (PLK1) TTIYVQP PLK1_HUMAN Modulator [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
3 Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
6 J Clin Oncol 29: 2011 (suppl; abstr 3012).
7 TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther. 2012 Mar;11(3):700-9.
8 Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals.
9 BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.